Intarcia Appoints James P. Brady Vice President, Human Resources

BOSTON, May 1, 2015 /PRNewswire/ -- Intarcia Therapeutics, Inc. today announced the appointment of James P. Brady as Vice President, Human Resources, reporting directly to Kurt Graves, Intarcia's Chairman, President and CEO. As a new key member of the senior leadership team, Mr. Brady will work closely with the CEO and Leadership Team to assure the Company advances its business, brings in and retains top talent, and further embeds its core values and its dynamic culture. Another essential goal for Mr. Brady is to design, implement and evaluate programs to attract, retain, reward, and motivate top talent and top performance. The VP of Human Resources must support and sustain the high growth of Intarcia's U.S. infrastructure required to successfully commercialize Intarcia's late-stage development candidate for the treatment of type 2 diabetes, ITCA 650 (a once- or twice-yearly continuous subcutaneous delivery of exenatide).

James Brady joins Intarcia as its first VP of Human Resources after almost a decade at Genzyme Corporation.
"We are now in a vitally important period of high growth, so I am pleased and excited to welcome Jamie as a key part of our leadership," said Mr. Graves. "Jamie is an HR executive that will bring a laser focus to supporting our mission-critical plans, our talent needs, and driving the business forward. He isn't an academically focused HR guru, he is a 'people person' who dislikes politics like the rest of us, and he wants to be a key and accountable part of building a fast-paced, highly innovative, fun, and successful biotech company. Human Resources is critical as we advance ITCA 650 toward commercialization in the U.S., realizing that Intarcia alone is the driving force for our success here in the massive domestic market place. I have every confidence that Jamie, with the full support of our team, will be a well timed and tremendously appreciated asset for Intarcia as we become a more fully operational corporate enterprise capable of launching disruptively innovative products in ways that set new standards of excellence in our industry pioneering pathways for which there are no analogs. The scope of these aspirations requires exquisite talent management, and Jamie's arrival, skills and dedication give me every confidence we are on track to meet the challenges behind our opportunities."

Mr. Brady has more than 15 years of professional leadership experience educating top talent and building more aligned organizations. He most recently worked at Genzyme Corporation for almost a decade, half before and half after the Sanofi acquisition. His latest position was as Senior Director & Head of Global Industrial Operations Learning & Development at Genzyme, a Sanofi Company, where he supported the manufacture of approximately $3 billion in commercial product with a central team and global network within manufacturing, distribution and core functions. Prior to that, he served as Director and then Senior Director, Leadership & Organization Development at Genzyme.

Before working at Genzyme, Mr. Brady worked for approximately six years at Thomson Financial in areas such as executive learning, talent management processes, executive coaching and mentoring, and executive leadership programs. Specifically, Mr. Brady served as Director, Talent Development, and as Director, Leadership Development at Thomson Financial. Prior to that, he held a variety of educational positions focused on leadership and management-related topics. Mr. Brady holds a Bachelor of Arts degree in History from Marietta College, and a Master of Theological Studies degree from Harvard University. He also has additional management and professional learning coursework completed at MIT's Sloan School of Management, Babson College's School of Executive Education, and the University of Michigan'sRoss School of Business.

About Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. is an independent, privately held, biopharmaceutical company developing therapies to enhance treatment outcomes by optimizing and improving the efficacy, continuous administration and tolerability of drug therapies. In addition, delivering medicines just once- or twice-yearly has the potential to ensure improved patient adherence and compliance, which is very poor in most chronic diseases. Intarcia's drug development expertise and competitive edge are demonstrated by its abilities to stabilize proteins and peptides at above-body temperature and to deliver them in a constant and consistent manner via Intarcia's proprietary technology platform. Intarcia is conducting a phase 3-stage development program for type 2 diabetes that consists of four separate clinical trials, two of which have been completed. Intarcia continues to conduct research and development, utilizing its platform technology, to treat other chronic serious disorders in the field of diabetes, obesity and autoimmune diseases. For more information about Intarcia, please visit www.intarcia.com.

About ITCA 650
ITCA 650 (a once- or twice-yearly continuous subcutaneous delivery of exenatide) is being developed for the treatment of type 2 diabetes. The investigational therapy employs Intarcia's proprietary technology platform involving a matchstick-size, miniature osmotic pump that is placed sub-dermally to provide continuous and consistent drug therapy, and the company's proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for extended periods of time. Exenatide, the active agent in ITCA 650, is a glucagon-like peptide-1 (GLP-1) receptor agonist currently marketed globally as twice-daily and once-weekly self-injection therapies for type 2 diabetes. Upon approval, ITCA 650 would represent the first injection-free GLP-1 therapy that can deliver up to a full year of treatment from a single placement. ITCA 650 is currently in a global phase 3 clinical trial program called FREEDOM.

Intarcia and its logo are registered trademarks of Intarcia Therapeutics, Inc.

Suggested Articles

After beating the standard of care at keeping testosterone levels down, Myovant's prostate cancer drug fell short in patients with metastatic disease.

A Mount Sinai-led team found that immune cells in the brain protect it from abnormal activation that can lead to behavioral problems.

Results from the small cohort suggest the vaccine triggers comparable immune responses in younger and older adults.